Document Detail


Fibroblast growth factor 4 gene therapy for chronic ischemic heart disease.
MedLine Citation:
PMID:  18555186     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Therapeutic myocardial angiogenesis and arteriogenesis represent a novel treatment strategy for patients with angina refractory to traditional medical and surgical therapies. The fibroblast growth factors are a family of proteins that are known mediators of angio-/arteriogenesis. Based on promising preclinical animal data, a series of four randomized placebo-controlled clinical trials have been conducted to determine the safety and efficacy of local delivery of fibroblast growth factor 4 with the use of adenovirus-vector-mediated gene transfer to induce myocardial angio-/arteriogenesis in patients with stable angina. This review describes the scientific rationale underlying these clinical trials, provides an overview of their results, and discusses the implications for future studies.
Authors:
Navin K Kapur; Jeffrey J Rade
Related Documents :
9704686 - Fasting and postprandial ischemic threshold in patients with unstable angina with and w...
8901726 - Influence of sex on the use of cardiac procedures in patients presenting to the emergen...
3541606 - Unstable angina pectoris: the first half century: natural history, pathophysiology, and...
2871756 - Therapeutic choices in unstable angina.
25172906 - The efficacy and mechanism of dexmedetomidine in myocardial apoptosis via the renin-ang...
6858836 - Effects of oral dipyridamole on coronary dynamics and myocardial metabolism at rest and...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Trends in cardiovascular medicine     Volume:  18     ISSN:  1050-1738     ISO Abbreviation:  Trends Cardiovasc. Med.     Publication Date:  2008 May 
Date Detail:
Created Date:  2008-06-16     Completed Date:  2008-10-16     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9108337     Medline TA:  Trends Cardiovasc Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  133-41     Citation Subset:  IM    
Affiliation:
Division of Cardiology, Johns Hopkins School of Medicine, Baltimore, MD 21287, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adenoviridae / genetics
Animals
Chronic Disease
Clinical Trials as Topic
Collateral Circulation
Coronary Circulation
Fibroblast Growth Factor 4 / genetics,  metabolism*
Gene Therapy / adverse effects,  methods*
Gene Transfer Techniques
Genetic Vectors
Humans
Myocardial Ischemia / genetics,  metabolism,  physiopathology,  therapy*
Neovascularization, Physiologic*
Patient Selection
Time Factors
Treatment Outcome
Chemical
Reg. No./Substance:
0/Fibroblast Growth Factor 4

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Beyond receptor expression levels: the relevance of target accessibility in ligand-directed pharmaco...
Next Document:  Bioinformatics assessment of beta-myosin mutations reveals myosin's high sensitivity to mutations.